Target Price | $329.59 |
Price | $319.66 |
Potential | 3.11% |
Number of Estimates | 22 |
22 Analysts have issued a price target Amgen 2025 . The average Amgen target price is $329.59. This is 3.11% higher than the current stock price. The highest price target is $405.00 26.70% , the lowest is $200.00 37.43% . | |
A rating was issued by 32 analysts: 16 Analysts recommend Amgen to buy, 14 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2025 of 3.11% . Most analysts recommend the Amgen stock at Purchase. |
24 Analysts have issued a sales forecast Amgen 2024 . The average Amgen sales estimate is $33.2b . This is 8.03% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $33.8b 9.84% , the lowest is $32.6b 6.13% .
This results in the following potential growth metrics:
2023 | $28.0b | 7.35% |
---|---|---|
2024 | $33.2b | 18.54% |
2025 | $34.3b | 3.16% |
2026 | $34.7b | 1.24% |
2027 | $35.2b | 1.55% |
2028 | $36.3b | 3.12% |
7 Analysts have issued an Amgen EBITDA forecast 2024. The average Amgen EBITDA estimate is $19.6b . This is 69.74% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $23.5b 103.44% , the lowest is $18.3b 58.01% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $12.4b | 1.91% |
---|---|---|
2024 | $19.6b | 58.95% |
2025 | $18.4b | 6.06% |
2026 | $18.3b | 0.80% |
2027 | $19.1b | 4.21% |
2028 | $19.6b | 2.59% |
2023 | 44.11% | 8.62% |
---|---|---|
2024 | 59.15% | 34.09% |
2025 | 53.86% | 8.94% |
2026 | 52.77% | 2.02% |
2027 | 54.15% | 2.62% |
2028 | 53.88% | 0.50% |
10 Amgen Analysts have issued a net profit forecast 2024. The average Amgen net profit estimate is $3.5b . This is 12.50% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $5.6b 78.62% , the lowest is $2.2b 30.34% .
This results in the following potential growth metrics and future Net Margins:
2023 | $6.7b | 3.14% |
---|---|---|
2024 | $3.5b | 47.76% |
2025 | $5.2b | 47.64% |
2026 | $6.2b | 19.13% |
2027 | $8.6b | 39.13% |
2028 | $9.3b | 8.75% |
2023 | 23.95% | 3.92% |
---|---|---|
2024 | 10.56% | 55.92% |
2025 | 15.11% | 43.09% |
2026 | 17.78% | 17.67% |
2027 | 24.36% | 37.01% |
2028 | 25.69% | 5.46% |
10 Analysts have issued a Amgen forecast for earnings per share. The average Amgen <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $6.52 . This is 12.41% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $10.36 78.62% , the lowest is $4.04 30.34% .
This results in the following potential growth metrics and future valuations:
2023 | $12.49 | 3.14% |
---|---|---|
2024 | $6.52 | 47.80% |
2025 | $9.63 | 47.70% |
2026 | $11.48 | 19.21% |
2027 | $15.97 | 39.11% |
2028 | $17.36 | 8.70% |
Current | 55.07 | 203.92% |
---|---|---|
2024 | 48.99 | 11.04% |
2025 | 33.18 | 32.27% |
2026 | 27.85 | 16.06% |
2027 | 20.02 | 28.11% |
2028 | 18.41 | 8.04% |
Based on analysts' sales estimates for 2024, the Amgen stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 6.78 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 5.17 .
This results in the following potential growth metrics and future valuations:
Current | 7.32 | 12.79% |
---|---|---|
2024 | 6.78 | 7.38% |
2025 | 6.57 | 3.06% |
2026 | 6.49 | 1.22% |
2027 | 6.39 | 1.52% |
2028 | 6.20 | 3.03% |
Current | 5.59 | 2.40% |
---|---|---|
2024 | 5.17 | 7.43% |
2025 | 5.01 | 3.06% |
2026 | 4.95 | 1.23% |
2027 | 4.88 | 1.52% |
2028 | 4.73 | 3.03% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.